Atrium Therapeutics, Inc. Common Stock (NASDAQ:RNA) — Market Cap & Net Worth
Market Cap & Net Worth: Atrium Therapeutics, Inc. Common Stock (RNA)
Atrium Therapeutics, Inc. Common Stock (NASDAQ:RNA) has a market capitalization of $208.37 Million ($208.37 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16391 globally and #3707 in its home market, demonstrating a -3.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Atrium Therapeutics, Inc. Common Stock's stock price $13.43 by its total outstanding shares 15514966 (15.51 Million). Analyse cash flow conversion of Atrium Therapeutics, Inc. Common Stock to see how efficiently the company converts income to cash.
Atrium Therapeutics, Inc. Common Stock Market Cap History: 2020 to 2026
Atrium Therapeutics, Inc. Common Stock's market capitalization history from 2020 to 2026. Data shows change from $395.94 Million to $208.37 Million (-12.00% CAGR).
Index Memberships
Atrium Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #449 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1601 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.01% | #227 of 263 |
Weight: Atrium Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Atrium Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Atrium Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
60.11x
Atrium Therapeutics, Inc. Common Stock's market cap is 60.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $395.94 Million | $6.79 Million | -$43.98 Million | 58.34x | N/A |
| 2021 | $368.79 Million | $9.33 Million | -$117.37 Million | 39.54x | N/A |
| 2022 | $344.28 Million | $9.22 Million | -$169.08 Million | 37.32x | N/A |
| 2023 | $140.41 Million | $9.56 Million | -$212.22 Million | 14.69x | N/A |
| 2024 | $451.18 Million | $10.90 Million | -$322.30 Million | 41.40x | N/A |
| 2025 | $1.12 Billion | $18.62 Million | -$76.68 Million | 60.11x | N/A |
Competitor Companies of RNA by Market Capitalization
Companies near Atrium Therapeutics, Inc. Common Stock in the global market cap rankings as of May 5, 2026.
Key companies related to Atrium Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Atrium Therapeutics, Inc. Common Stock Historical Marketcap From 2020 to 2026
Between 2020 and today, Atrium Therapeutics, Inc. Common Stock's market cap moved from $395.94 Million to $ 208.37 Million, with a yearly change of -12.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $208.37 Million | -81.38% |
| 2025 | $1.12 Billion | +148.04% |
| 2024 | $451.18 Million | +221.33% |
| 2023 | $140.41 Million | -59.22% |
| 2022 | $344.28 Million | -6.65% |
| 2021 | $368.79 Million | -6.86% |
| 2020 | $395.94 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Atrium Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $208.37 Million USD |
| MoneyControl | $208.37 Million USD |
| MarketWatch | $208.37 Million USD |
| marketcap.company | $208.37 Million USD |
| Reuters | $208.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more